PTH is Typically Suppressed in Hypercalcemia of Malignancy
In hypercalcemia due to malignancy, parathyroid hormone (PTH) is characteristically low or suppressed, distinguishing it from primary hyperparathyroidism where PTH is elevated or inappropriately normal.
Pathophysiologic Mechanism
The underlying mechanism of malignancy-associated hypercalcemia most commonly involves parathyroid hormone-related peptide (PTHrP) secretion by tumors, which stimulates osteoclastic bone resorption 1. This PTHrP-mediated process—termed humoral hypercalcemia of malignancy (HHM)—accounts for the majority of cases 2, 1. The elevated calcium levels trigger normal physiologic feedback, suppressing endogenous PTH secretion from the parathyroid glands.
Diagnostic Approach: PTH as the Critical Discriminator
PTH measurement is the single most useful test for differentiating malignancy-associated hypercalcemia from primary hyperparathyroidism 3. The pattern is clear:
- Malignancy: PTH is suppressed (typically <10 pg/mL) 4
- Primary hyperparathyroidism: PTH is elevated or inappropriately normal despite hypercalcemia 3
Key Clinical Distinctions
When evaluating hypercalcemia, look for these specific patterns 3:
Malignancy-associated hypercalcemia:
- Rapid onset of symptoms
- Higher calcium levels (often >12 mg/dL, can exceed 14 mg/dL)
- Marked anemia present
- No kidney stones
- No metabolic acidosis
- Suppressed PTH
Primary hyperparathyroidism:
- Chronic course (>6 months)
- Lower calcium levels (<12 mg/dL typically)
- Kidney calculi common
- Hyperchloremic metabolic acidosis
- Elevated or inappropriately normal PTH
Important Nuance: The PTH-PTHrP Relationship
Recent evidence reveals that even in malignancy-associated hypercalcemia, low but detectable PTH levels may correlate more strongly with calcium severity than PTHrP levels themselves 4. In one study of 48 patients with malignancy-associated hypercalcemia, serum calcium correlated more strongly with PTH (r=0.49, p=0.003) than with PTHrP (r=0.35, p=0.029), suggesting that residual PTH secretion—though suppressed—may still contribute to severe hypercalcemia 4.
Critical Caveat: Overlap Exists
While PTH is typically suppressed in malignancy, mild PTHrP elevations can occur in non-malignant conditions 5. When PTH is ≥30 pg/mL and PTHrP is <7.0 pmol/L, the probability of cancer is <5%; when PTHrP is <9.0 pmol/L with PTH ≥30 pg/mL, cancer probability remains <10% 5. This means:
- Measure both PTH and PTHrP simultaneously for optimal diagnostic accuracy
- PTH >30 pg/mL with mildly elevated PTHrP suggests non-malignant causes (primary hyperparathyroidism, absorptive hypercalcemia)
- Suppressed PTH with elevated PTHrP strongly suggests malignancy
Rare Exception: PTH-Secreting Tumors
In the uncommon scenario of parathyroid carcinoma or ectopic PTH secretion, PTH will be elevated despite malignancy 2. These cases require calcimimetics rather than standard antiresorptive therapy 1. However, this represents a distinct minority of malignancy-associated hypercalcemia cases.